Our study found that osimertinib is a clinically effective standard regimen in patients with LM associated with EGFR + NSCLC, regardless of T790M mutation that confers drug resistance, with a median LM PFS of 9.50 months and a mOS of 13.15 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.